Canaccord Genuity Group Trims Medexus Pharmaceuticals (CVE:MDP) Target Price to C$2.75

Medexus Pharmaceuticals (CVE:MDPGet Rating) had its price target decreased by Canaccord Genuity Group from C$3.50 to C$2.75 in a research report released on Thursday, BayStreet.CA reports.

A number of other equities analysts have also commented on the stock. Raymond James lowered shares of Medexus Pharmaceuticals from an outperform rating to a market perform rating and cut their price objective for the company from C$4.50 to C$2.00 in a research report on Tuesday. Stifel Nicolaus dropped their target price on shares of Medexus Pharmaceuticals from C$14.25 to C$11.00 in a research report on Wednesday, August 10th.

Medexus Pharmaceuticals Price Performance

MDP stock opened at C$7.75 on Thursday. The firm has a 50 day moving average of C$7.75 and a 200-day moving average of C$7.75. The company has a current ratio of 1.19, a quick ratio of 0.74 and a debt-to-equity ratio of 1,174.36. Medexus Pharmaceuticals has a 12 month low of C$2.80 and a 12 month high of C$9.75. The firm has a market capitalization of C$148.54 million and a P/E ratio of -4.28.

About Medexus Pharmaceuticals

(Get Rating)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older.

Read More

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with's FREE daily email newsletter.